232 related articles for article (PubMed ID: 16039774)
21. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Scorilas A; Bharaj B; Giai M; Diamandis EP
Br J Cancer; 2001 Mar; 84(6):760-7. PubMed ID: 11259089
[TBL] [Abstract][Full Text] [Related]
22. Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population?
Mishra D; Thangaraj K; Mandhani A; Kumar A; Mittal R
Clin Genet; 2005 Jul; 68(1):55-60. PubMed ID: 15952987
[TBL] [Abstract][Full Text] [Related]
23. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
Liu JH; Li HW; Tong M; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984
[TBL] [Abstract][Full Text] [Related]
24. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
Mononen N; Ikonen T; Syrjäkoski K; Matikainen M; Schleutker J; Tammela TL; Koivisto PA; Kallioniemi OP
Br J Cancer; 2001 May; 84(10):1344-7. PubMed ID: 11355945
[TBL] [Abstract][Full Text] [Related]
25. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
[TBL] [Abstract][Full Text] [Related]
26. Significant impact of 5alpha-reductase type 2 polymorphisms on sperm concentration and motility.
Elzanaty S; Giwercman YL; Giwercman A
Int J Androl; 2006 Jun; 29(3):414-20. PubMed ID: 16487406
[TBL] [Abstract][Full Text] [Related]
27. [Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-alphareductase in a population of Afro-Caribbean population with prostate cancer].
Veronique-Baudin J; Dieye M; Kouyoumdjian JC; Vacheron F; Draganescu C; Azaloux H
Prog Urol; 2006 Jun; 16(3):303-10. PubMed ID: 16821341
[TBL] [Abstract][Full Text] [Related]
28. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
[TBL] [Abstract][Full Text] [Related]
29. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?
Zeegers MP; Kiemeney LA; Nieder AM; Ostrer H
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1765-71. PubMed ID: 15533905
[TBL] [Abstract][Full Text] [Related]
30. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
[TBL] [Abstract][Full Text] [Related]
31. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
32. Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis.
Ishii T; Sasaki G; Hasegawa T; Sato S; Matsuo N; Ogata T
J Urol; 2004 Jul; 172(1):319-24. PubMed ID: 15201804
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
Giwercman C; Giwercman A; Pedersen HS; Toft G; Lundin K; Bonde JP; Lundberg Giwercman Y
Int J Androl; 2008 Feb; 31(1):25-30. PubMed ID: 17376218
[TBL] [Abstract][Full Text] [Related]
34. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
[TBL] [Abstract][Full Text] [Related]
35. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):618-24. PubMed ID: 12869400
[TBL] [Abstract][Full Text] [Related]
36. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer.
Schatzl G; Madersbacher S; Haitel A; Gsur A; Preyer M; Haidinger G; Gassner C; Ochsner M; Marberger M
J Urol; 2003 Apr; 169(4):1312-5. PubMed ID: 12629350
[TBL] [Abstract][Full Text] [Related]
37. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis.
Shibata A; Garcia MI; Cheng I; Stamey TA; McNeal JE; Brooks JD; Henderson S; Yemoto CE; Peehl DM
Prostate; 2002 Sep; 52(4):269-78. PubMed ID: 12210487
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk.
Andersson P; Varenhorst E; Söderkvist P
Eur J Cancer; 2006 Nov; 42(16):2833-7. PubMed ID: 17010601
[TBL] [Abstract][Full Text] [Related]
40. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
Allen NE; Reichardt JK; Nguyen H; Key TJ
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
